Paragraph 4

The following medicinal products shall be available only from a pharmacy unless they are the subject of a F1UK marketing authorisation F2..., Article 126a authorisation, parallel import licence or traditional herbal registration that classifies them as medicinal products subject to general sale—

(a)

a product that is for use as an anthelmintic;

(b)

a product that is for parenteral administration;

(c)

a product that is for use as an enema;

(d)

a product that is for use wholly or mainly for irrigation of—

(i)

wounds, or

(ii)

the bladder, vagina or rectum;

(e)

a product that is for administration wholly or mainly to children being a preparation of aloxiprin or aspirin.

Annotations

Textual amendments

F1: Words in Sch. 1 para. 4 substituted (31.12.2020) by S.I. 2019/775, reg. 8(b) (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 5)
F2: Words in Sch. 1 para. 4 omitted (1.1.2025) by virtue of The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024 (S.I. 2024/832), regs. 1(1), 134(b)